There was a positive correlation between the percent of decrease of IL-17 and the percent of increase of iTregs (Figure 5L), suggesting that the increase of iTreg development by LLL12b treatment may contribute to the suppression of IL-17 production in CD4+ T cells from MS patients. This evidence concerns the gene CD4 and myeloid sarcoma.